Glycomine’s Series C raise highlights investor confidence in the company amid pressure on the paediatric rare disease sector.

In an overall comparison of the treatment groups, idebenone did not significantly affect the degree of change from baseline to 6 months in International Cooperative Ataxia Rating Scale (ICARS ...

treatment with GLM101 led to an average 11.9-point improvement on the ICARS (International Cooperative Ataxia Rating Scale) over 24 weeks. "We are impressed by the therapeutic approach and strong ...